Creating virtuous cycles in drug development with Rob Freishtat
Send us Fan Mail
Rob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space.
• Current market uncertainty and investment challenges in biotech, especially for rare disease research
• Approximately two-thirds of clinical trial processes add no value and aren't required by regulations
• Many clinical trial failures occur not because drugs don't work but because trials can't recruit enough patients
• Companies often treat development phases as…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.